Endothelial injury and inflammation in patients with hyperuricemic nephropathy at chronic kidney disease stages 1-2 and 3-4

doi:10.12998/wjcc.v10.i32.11766

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 10, Issue 32

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3604)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-3) series.

Item

Count

PDF

149

WORD

HTML

1730

Tables (1-3)

307

Sum=2216

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

303

Download

1025

Sum=1328

Nov 16, 2022 (publication date) through Feb 8, 2025

Times Cited of This Article

Times Cited (5)

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

World J Clin Cases. Nov 16, 2022; 10(32): 11766-11774
Published online Nov 16, 2022. doi: 10.12998/wjcc.v10.i32.11766

Table 1 General data of patients in stages chronic kidney disease 1-2 and chronic kidney 3-4

Items		CKD 1-2 (n = 49)	CKD 3-4 (n = 31)	t/Z/χ²	P value
Age (yr)		42 (35-52)	66 (61-69)	6.514	< 0.001^c
Sex	Male	48 (98.0%)	29 (93.5%)	1.023	0.312
Sex	Female	1 (2.0%)	2 (6.5%)
Course of gout (mo)		45.7 (14.8-80.55)	81.3 (39.3-173.63)	2.583	0.010^a
Heart rate (beats/min)		75.04 ± 9.836	74.87 ± 8.62	0.079	0.937
BMI		25.95 (24.54-27.66)	24.77 (24.00-27.28)	-1.487	0.137
Systolic pressure (mmHg)		129.18 ± 10.55	130.61 ± 10.70	-0.587	0.559
Diastolic pressure (mmHg)		83.94 ± 8.59	82.97 ± 6.44	0.540	0.591
Incidence of hypertension %		39 (79.6%)	30 (96.8%)	4.727	0.030^a
SUA (umol/L)		474.41 ± 102.34	483.90 ± 107.97	-0.396	0.693
Scr (mmol/L)		92.78 ± 12.55	145.87 ± 48.14	-7.360	< 0.001^c
BUN (mmol/L)		5.20 ± 1.06	9.35 ± 3.46	-7.857	< 0.001^c
eGFR (ml/min/1.73 m²)		91.73 ± 14.82	40.91 ± 11.84	16.111	< 0.001^c
Urine NAG (U/L)		0.70 (0.10-5.08)	0.70 (2.05-14.82)	3.402	0.001^b
Urine RBP (mg/L)		0.20 (0.10-0.30)	0.58 (0.20-1.95)	3.059	0.002^b
Urine β2-MG (mg/L)		0.20 (0.10-0.30)	0.30 (0.12-1.91)	2.615	0.009^b
Urine Alb/Cr (mg/g)		4.79 (2.07-9.04)	45.76 (8.22-316.75)	4.504	< 0.001^c

^aP < 0.05.

^bP < 0.01.

^cP < 0.001.

CKD: Chronic kidney disease; BMI: Body mass index; SUA: Serum uric acid; Scr: Serum creatinine; BUN: Blood urea nitrogen; eGFR: Estimated glomerular filtration rate; NAG: N-acetyl-beta-D-glucosidase; RBP: Retinol binding protein; β2-MG: β2-Microglobulin; Alb/Cr: Albumin-to-creatinine.

Table 2 Differences in levels of biomarkers between chronic kidney disease 1-2 and chronic kidney 3-4

Markers (plasm or urine)	CKD 1-2 (n = 49)	CKD 3-4 (n = 31)	t/Z	P value
Plasm heparan sulfate (pg/mL)	410.37 (174.13-608.45)	853.59 (646.14-1032.49)	4.763	< 0.001^c
Plasm endocan (pg/mL)	81.78 (48.23-120.75)	131.33 (60.02-199.01)	2.115	0.034^a
Plasm Ox-LDL (ng/mL)	2.65 (1.58-3.67)	3.58 (1.94-5.03)	1.760	0.078
Plasm E-selectin (pg/mL)	396.33 (274.44-548.49)	558.75 (488.06-733.80)	3.672	< 0.001^c
Plasm slCAM1 (ng/mL)	662.03 ± 32.28	991.55 ± 64.83	-4.906	< 0.001^c
Urine L-PGDS (ng/mL)	0.10 (0.08-0.39)	0.63 (0.19-1.28)	3.580	< 0.001^c
Plasm IL-1β (pg/mL)	33.42 (31.63-36.38)	36.60 (33.20-39.74)	2.732	0.006^b
Plasm IL-6 (pg/mL)	12.12 (10.04-15.17)	18.16 (11.43-20.86)	2.899	0.004^b
Urine IL-1β (pg/mL)	7.16 (5.46-12.16)	12.00 (7.84-18.24)	2.928	0.003^b
Urine IL-6 (pg/mL)	2.18 (01.39-3.83)	7.42 (3.57-14.16)	4.370	< 0.001^c

^aP < 0.05.

^bP < 0.01.

^cP < 0.001.

CKD: chronic kidney disease; Ox-LDL: Oxidized low density lipoprotein; slCAM1: Soluble intercellular adhesion molecule-1; L-PGDS: Lipocalin-type prostaglandin D synthase; IL: Interleukin.

Table 3 Chronic kidney disease multivariate logistic regression analysis of staging and markers of endothelial injury and inflammation levels

Makers (plasm or urine)	B	Wald	Exp(B)	95%CI	Sig
Plasm heparan sulfate (pg/mL)	0.004	5.845	1.004	1.001-1.008	0.016^a
Plasm endocan (pg/mL)	< 0.001	< 0.001	1.000	0.987-1.014	0.987
Plasm Ox-LDL (ng/mL)	-0.214	0.606	0.807	0.471-1.384	0.436
Plasm E-selectin (pg/mL)	0.002	0.644	1.002	0.997-1.007	0.422
Plasm slCAM1 (ng/mL)	2.178	6.952	8.831	1.749-44.588	0.008^b
Plasm L-PGDS (ng/mL)	0.033	0.002	1.034	0.195-5.490	0.969
Plasm IL-1β (pg/mL)	-0.046	0.952	0.955	0.870-1.048	0.329
Plasm IL-6 (pg/mL)	-0.041	0.421	0.960	0.848-1.087	0.516
Urine IL-1β (pg/mL)	-0.010	0.016	0.990	0.847-1.157	0.901
Urine IL-6 (pg/mL)	0.046	0.126	1.047	0.813-1.348	0.723

^aP < 0.05.

^bP < 0.01.

^cP < 0.001.

CKD: Chronic kidney disease; Ox-LDL: Oxidized low density lipoprotein; slCAM1: Soluble intercellular adhesion molecule-1; L-PGDS: Lipocalin-type prostaglandin D synthase; IL: Interleukin; B: Partial regression coefficient; Wald: χ² value; Exp(B): Odds ratio; CI: Confidence interval; Sig: Significance.

Citation: Xu L, Lu LL, Wang YT, Zhou JB, Wang CX, Xin JD, Gao JD. Endothelial injury and inflammation in patients with hyperuricemic nephropathy at chronic kidney disease stages 1-2 and 3-4. World J Clin Cases 2022; 10(32): 11766-11774
URL: https://www.wjgnet.com/2307-8960/full/v10/i32/11766.htm
DOI: https://dx.doi.org/10.12998/wjcc.v10.i32.11766